Bladder Carcinoma Clinical Trials

A listing of Bladder Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 259 clinical trials
Featured trial
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder …

cancer of the ovary
measurable disease
bladder tumor
  • 11 Jul, 2022
  • 19 locations
Featured trial
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

bladder cancer
urothelial carcinoma
metastatic urothelial carcinoma
bladder carcinoma
  • 10 May, 2022
  • 64 locations
Featured trial
Non-Muscle Invasive Bladder Cancer BOND-003

People with Non-Muscle Invasive Bladder Cancer are asked to participate in a research study being conducted by Montefiore Medical Center. 

bladder tumor
radical cystectomy
invasive bladder cancer
  • 03 Aug, 2021
  • 1 location
Therapeutic Instillation of Mistletoe (TIM)

The aim of this phase III study is to assess the efficacy of abnobaVISCUM® 900 compared with Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of the

  • 13 May, 2022
  • 23 locations
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study

This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not completely resectable. Patients will receive treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for …

  • 30 Jun, 2022
  • 1 location
OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer

This Ⅱ study evaluates the safety and efficacy of intratumoral injection of OH2 in locally advanced or metastatic bladder cancer. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of …

  • 10 Aug, 2022
  • 1 location
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

Neoadjuvant accelerated methotrexate/vinblastine/adriamycin/cisplatin (AMVAC) in combination with nivolumab is under evaluation for the treatment of muscle invasive bladder cancer (MIBC). Patients with pre-specified tumor mutations and complete clinical response with neoadjuvant therapy will preserve their bladders and go on active surveillance.

  • 22 Apr, 2022
  • 1 location
Re-optimization Based Online Adaptive Radiotherapy of Bladder Cancer

This is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle invasive bladder cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).

  • 29 Jul, 2022
  • 1 location
  • 26 Apr, 2022
  • 1 location
EffectiveNess of a Multimodal preHAbilitation Program in Patients With Muscle iNvasive Bladder canCEr. The ENHANCE Randomized Controlled Trial (ENHANCE)

Currently, the potential value of a multimodal prehabilitation program in muscle invasive bladder cancer has not been extensively studied. The investigators designed the ENHANCE study to assess the effect of a structured multimodal prehabilitation program in 154 patients with muscle invasive bladder cancer on the number (primary endpoint) and severity …

  • 15 Sep, 2022
  • 1 location